NephroCheck data compared to serum creatinine in various clinical settings

Area of Science:

• Nephrology
• Biomarker Discovery
• Critical Care Medicine

Background:

• Acute kidney injury (AKI) is a common complication in intensive care units, post-surgery, and following toxic drug exposure.
• Rising serum creatinine and falling urine output indicate tubular cell injury, often occurring after the damage has begun.
• This study investigated two cell-cycle arrest urinary biomarkers against serum creatinine in four distinct clinical settings.

Observation:

• The NephroCheck assay measures urinary insulin-like growth factor binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinase-2 (TIMP-2).
• The AKIRisk score, derived from these biomarkers, is determined via a sandwich immunoassay.
• These urinary biomarkers increase before observable changes in serum creatinine levels.

Findings:

• The combined urinary biomarkers [IGFBP7]·[TIMP-2] rise rapidly, preceding alterations in serum creatinine.
• A swift decrease in the AKIRisk score is a strong predictor of kidney function recovery across all studied clinical scenarios.
• The test demonstrated potential in detecting subclinical kidney injury.

Implications:

• The bedside AKIRisk test offers early detection of renal injury.
• A declining AKIRisk score correlates with restored kidney function, while persistently high scores suggest progression to end-stage renal disease.
• Further research is necessary to fully elucidate the differing biomarker dynamics based on injury etiology and severity.